IDT Biologika, a global contract development and manufacturing organization (CDMO), has appointed Federico Pollano as Chief Commercial Officer, effective March 1, 2025.

“In Federico Pollano, we have found an outstanding personality for this position, both personally and professionally. We want to strengthen our global network and strategically expand our business, and Federico Pollano’s many years of experience in the CDMO business will provide us with important inspiration,” remarks Dr. Sally Choe, Co-CEO IDT Biologika.

Experience

Federico Pollano has extensive experience in management positions at global CDMOs in the pharmaceutical and biotechnology industry.

Prior to joining IDT Biologika he was Senior Vice President Business Development at Rentschler Biopharma for the past seven years. During this period, he assumed responsibility for sales management and customer service. He also joined the Extended Executive Board in 2023. Before taking on this role, Pollano built up the CDMO business as Global Director Contract Manufacturing and Business Development at Polpharma Biologics and was Managing Director at Richter-Helm-BioTec and Executive Manager Pharmaceuticals at Helm Pharmaceuticals. He also previously held important stations at GSK and Ratiopharm.

“I am very much looking forward to my new role at IDT Biologika and especially to contributing my skills and dedication to this great team,” Pollano remarks. “IDT has already established itself as a reliable partner in the market and is currently experiencing growth alongside SK bioscience. I am excited about contributing to this growth, particularly by strengthening and expanding relationships with customers and leveraging the full range of IDT’s capabilities to ensure the success of our clients’ projects.”